Johnson & Johnson $JNJ Holdings Cut by Inscription Capital LLC

Key Points

• Inscription Capital cut its Johnson & Johnson stake by 13.9% in the third quarter, selling 4,140 shares and retaining 25,696 shares valued at about $6.8 million.
• J&J beat quarterly earnings expectations with EPS of $2.59 versus $2.53 estimated, while revenue rose 5.9% year over year to $25.4 billion. The company declared a quarterly dividend of $1.34 per share, equivalent to a 2.0% yield.
• Analysts’ consensus rating is “Moderate Buy”, with an average price target of $275.92; two executives also reported significant share sales.

Inscription Capital LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,696 shares of the company's stock after selling 4,140 shares during the quarter. Johnson & Johnson accounts for 0.7% of Inscription Capital LLC's portfolio, making the stock its 22nd biggest holding. Inscription Capital LLC's holdings in Johnson & Johnson were worth $6,803,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. CKW Financial Group raised its position in shares of Johnson & Johnson by 0.9% in the 3rd quarter. CKW Financial Group now owns 4,269 shares of the company's stock worth $1,104,000 after purchasing an additional 37 shares during the last quarter. Silver Coast Investments LLC grew its position in Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock valued at $271,000 after purchasing an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV grew its position in Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after purchasing an additional 39 shares during the last quarter. Triumph Capital Management increased its stake in Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after purchasing an additional 39 shares in the last quarter. Finally, Kwmg LLC increased its stake in Johnson & Johnson by 1.7% during the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company's stock valued at $631,000 after purchasing an additional 39 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by corporate insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase across its portfolio, providing a modest institutional-demand signal. Article: State Street Health Care SPDR Adds Eli Lilly and J&J
• Positive Sentiment: One analyst roundup described Wall Street as moderately bullish on J&J’s prospects, following the stock’s strong performance over the past year. Article: Are Wall Street Analysts Predicting Johnson & Johnson Stock Will Climb or Sink?
• Neutral Sentiment: Several articles highlighted J&J as a long-term dividend stock, including lists of companies with long records of annual payout increases. This supports its income-investment appeal, but the pieces offer no new company-specific dividend announcement. Article: 4 Dividend Kings That Could Pay You for the Rest of Your Retirement
• Neutral Sentiment: A value-investing comparison examined J&J alongside Bayer, while another article addressed concerns that J&J shares may look expensive; the supplied headlines do not specify a valuation conclusion. Article: BAYRY vs. JNJ: Which Stock Is the Better Value Option?
• Negative Sentiment: Smith+Nephew said merger discussions with J&J’s orthopaedics unit had failed. This removes a potential transaction, though the article headline provides no details on the talks’ terms or financial implications for J&J. Article: Smith+Nephew Cuts Outlook, Confirms Failed Merger Talks with J&J’s Orthopaedics Unit

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $272.49 on Friday. Johnson & Johnson has a fifty-two week low of $185.12 and a fifty-two week high of $282.02. The business has a 50-day simple moving average of $265.71 and a two-hundred day simple moving average of $248.01. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The firm has a market cap of $655.97 billion, a price-to-earnings ratio of 41.29, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson's dividend payout ratio is 81.21%.

Analysts Set New Price Targets

Several research analysts have issued reports on JNJ shares. Bank of America reaffirmed a "neutral" rating and issued a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. Guggenheim reiterated a "buy" rating and set a $287.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 7th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a research report on Thursday, October 15th. Royal Bank Of Canada decreased their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating for the company in a report on Wednesday, October 14th. Finally, HSBC upped their price objective on Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $275.92.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.